Skip to main content
Midas Edge

IONIS PHARMACEUTICALS INC

For the period ended Sep 30, 2025. Filed Oct 29, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 29, 2025

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Total
DescriptionSharesAmountPaid in CapitalComprehensive LossAccumulated DeficitStockholders' Equity
Balance at June 30, 2024146,025$146$2,303,369$(34,838)$(2,004,979)$263,698
Net loss----(140,480)(140,480)
Change in unrealized gains, net of tax---10,315-10,315
Foreign currency translation---350-350
Issuance of common stock in connection with employee stock plans, net288-7,002--7,002
Issuance of public common stock, net11,50012489,081--489,093
Stock-based compensation expense--32,490--32,490
Balance at September 30, 2024157,813$158$2,831,942$(24,173)$(2,145,459)$662,468
Balance at June 30, 2025159,197$159$2,932,747$(27,987)$(2,273,195)$631,724
Net loss----(128,606)(128,606)
Change in unrealized gains, net of tax---2,091-2,091
Foreign currency translation---(82)-(82)
Issuance of common stock in connection with employee stock plans, net1,941281,257--81,259
Stock-based compensation expense--31,581--31,581
Balance at September 30, 2025161,138$161$3,045,585$(25,978)$(2,401,801)$617,967

Index

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · Additional · Accumulated Other · Total
DescriptionSharesAmountPaid in CapitalComprehensive LossAccumulated DeficitStockholders' Equity
Balance at December 31, 2023144,341$144$2,215,098$(32,645)$(1,795,911)$386,686
Net loss----(349,548)(349,548)
Change in unrealized gains, net of tax---8,259-8,259
Foreign currency translation---213-213
Issuance of common stock in connection with employee stock plans, net1,972233,205--33,207
Issuance of public common stock, net11,50012489,081--489,093
Stock-based compensation expense--94,558--94,558
Balance at September 30, 2024157,813$158$2,831,942$(24,173)$(2,145,459)$662,468
Balance at December 31, 2024157,909$158$2,868,812$(30,811)$(2,249,808)$588,351
Net loss----(151,993)(151,993)
Change in unrealized gains, net of tax---4,088-4,088
Foreign currency translation---745-745
Issuance of common stock in connection with employee stock plans, net3,229384,784--84,787
Stock-based compensation expense--91,989--91,989
Balance at September 30, 2025161,138$161$3,045,585$(25,978)$(2,401,801)$617,967

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.